| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 178 | 198 | 193 | 203 | 205 | 225 | 225 | 210 | 146 | 291 | 279 | 294 | 346 | 308 | 296 | 312 | 283 | 305 | 292 | 284 | 280 | 310 | 293 | 334 | 316 | 353 | 325 | 352 | 394 | 430 |
| Expenses | 132 | 146 | 142 | 145 | 156 | 161 | 159 | 173 | 131 | 198 | 188 | 195 | 224 | 212 | 218 | 231 | 211 | 221 | 215 | 212 | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 |
| EBITDA | 46 | 53 | 51 | 58 | 49 | 64 | 66 | 37 | 15 | 94 | 90 | 99 | 122 | 96 | 78 | 81 | 72 | 83 | 77 | 72 | 66 | 76 | 67 | 83 | 81 | 93 | 75 | 69 | 97 | 109 |
| Operating Profit % | 25 % | 25 % | 26 % | 28 % | 24 % | 28 % | 29 % | 16 % | 8 % | 32 % | 32 % | 33 % | 31 % | 30 % | 26 % | 24 % | 24 % | 26 % | 25 % | 25 % | 23 % | 24 % | 22 % | 24 % | 25 % | 26 % | 22 % | 18 % | 23 % | 25 % |
| Depreciation | 5 | 5 | 5 | 5 | 8 | 9 | 11 | 11 | 10 | 11 | 11 | 14 | 13 | 15 | 17 | 18 | 21 | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 |
| Interest | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 3 | 5 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 |
| Profit Before Tax | 42 | 48 | 46 | 52 | 39 | 53 | 53 | 23 | 4 | 81 | 78 | 82 | 103 | 78 | 56 | 57 | 43 | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 |
| Tax | 14 | 18 | 14 | 17 | 12 | 10 | 11 | 8 | 1 | 21 | 19 | 20 | 28 | 19 | 15 | 16 | 9 | 14 | 12 | 8 | 10 | 13 | 10 | 14 | 13 | 15 | 11 | 7 | 16 | 18 |
| Net Profit | 27 | 30 | 31 | 35 | 27 | 43 | 42 | 16 | 3 | 61 | 59 | 61 | 75 | 58 | 41 | 40 | 34 | 41 | 36 | 34 | 29 | 36 | 27 | 37 | 38 | 47 | 32 | 29 | 45 | 53 |
| EPS in ₹ | 4.83 | 6.14 | 6.26 | 6.87 | 5.34 | 8.57 | 8.38 | 3.09 | 0.57 | 11.88 | 11.50 | 12.05 | 14.65 | 11.39 | 8.02 | 7.81 | 6.53 | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.12 | 5.69 | 8.70 | 10.17 |
Metropolis Healthcare
Metropolis Healthcare
1,963.90
-41.90
(-2.09%)
Q1 Quarterly Results are out. Check out the updated financials1 day ago
View
Key Fundamentals
Market Cap
10,391.50 Cr
EPS
28.29
PE Ratio
63.88
Dividend Yield
0.00 %
Industry
Healthcare Services 52 Week High
2,263.00
52 Week Low
1,315.00
PB Ratio
7.08
Debt to Equity
0.17
Sector
Healthcare Service Provider Analyst Rating and Forecast
- By Refinitiv from17 analysts
Actual
Company News
View All News
Metropolis Healthcare is progressing with the integration of Core Diagnostics, which it acquired for Rs 247 crore in late 2024. The company expects Core Diagnostics to achieve double-digit margins by the end of FY26, improving from breakeven in Q4FY25 to low single-digit margins in Q1FY26 and high single-digit margins in Q2FY26. Managing Director Surendran Chemmenkotil stated that Core Diagnostics' margins should align with Metropolis' overall margins within three years of acquisition. The acquisition was aimed at strengthening the company's cancer diagnostics portfolio and expanding presence in Northern and Eastern India. Metropolis reported strong quarterly results with revenue rising 22.7% to Rs 429 crore, EBITDA up 20.4% to Rs 108 crore, and net profit increasing 13.2% to Rs 52.7 crore. The company's TruHealth segment is showing 20% growth.
Metropolis Healthcare announced during a conference call that the company expects volume growth of 10-11% for the year.
Metropolis has confirmed its organic business growth target of 70-100 basis points for FY26. This target was communicated during a conference call update.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
3,096.70 | #1 26,037.40 | 48.09 | #1 2,554.80 | 11.28 | #1 492 | 16.36 | 45.98 | |
1,023.60 | 10,457.90 | 69.16 | 699.70 | 23.06 | 144 | 2.85 | 56.20 | |
1,963.90 | #3 10,391.50 | #8 63.88 | #2 1,346.30 | #9 10.64 | #2 146 | #6 13.28 | 45.98 | |
1,391.10 | 7,017.50 | 58.36 | 702.20 | 20.80 | 91 | 81.06 | 64.18 | |
724.30 | 2,349.50 | 29.22 | 742.70 | 16.70 | 78 | 22.45 | 30.62 | |
319.65 | 1,691.60 | 51.19 | 255.90 | 15.11 | 31 | 19.48 | 58.30 | |
1,327.50 | 1,136.70 | 23.26 | 111.60 | 28.72 | 48 | 11.50 | 40.06 | |
289.65 | 922.00 | #1 -6.16 | 1,170.80 | -18.47 | -134 | -35.12 | 38.07 | |
402.10 | 760.30 | 29.66 | 147.80 | #1 134.60 | 19 | #1 444.44 | 74.75 | |
142.25 | 99.30 | 66.31 | 41.80 | 13.28 | 2 | 0.00 | 32.99 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
10.64 %
Net Income Growth
13.23 %
Cash Flow Change
-0.50 %
ROE
-6.76 %
ROCE
-11.55 %
EBITDA Margin (Avg.)
-1.42 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Fixed Assets | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 |
| Current Assets | 300 | 305 | 397 | 609 | 393 | 303 | 316 | 346 |
| Capital Work in Progress | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 |
| Investments | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 |
| Other Assets | 221 | 301 | 439 | 651 | 450 | 347 | 323 | 349 |
| Total Liabilities | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Current Liabilities | 91 | 125 | 170 | 204 | 302 | 265 | 246 | 294 |
| Non Current Liabilities | 11 | 8 | 58 | 92 | 341 | 246 | 210 | 238 |
| Total Equity | 429 | 420 | 525 | 708 | 888 | 991 | 1,099 | 1,335 |
| Reserve & Surplus | 405 | 409 | 513 | 696 | 876 | 978 | 1,086 | 1,313 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -23 |
| Investing Activities | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -199 |
| Operating Activities | 70 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 |
| Financing Activities | -10 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 50.38 % | 50.37 % | 50.33 % | 49.50 % | 49.79 % | 49.79 % | 49.76 % | 49.76 % | 49.75 % | 49.75 % | 49.74 % | 49.74 % | 49.67 % | 49.62 % | 49.43 % | 49.40 % | 48.90 % | 48.89 % | 48.89 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 24.29 % | 0.00 % | 18.90 % | 18.25 % | 18.56 % | 16.73 % | 15.29 % | 12.83 % | 12.52 % |
| DIIs | 15.34 % | 14.22 % | 11.77 % | 10.63 % | 15.32 % | 13.85 % | 11.88 % | 13.30 % | 13.64 % | 14.47 % | 16.86 % | 20.28 % | 24.86 % | 27.43 % | 28.02 % | 30.00 % | 30.30 % | 32.40 % | 33.10 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.95 % | 3.98 % | 4.24 % | 6.50 % | 9.14 % | 9.26 % | 9.45 % | 9.73 % | 8.53 % | 8.15 % | 7.78 % | 6.63 % | 5.24 % | 4.07 % | 3.54 % | 3.34 % | 3.84 % | 4.16 % | 3.69 % |
| Others | 30.33 % | 31.43 % | 33.66 % | 33.37 % | 25.75 % | 27.10 % | 28.91 % | 27.21 % | 28.08 % | 27.62 % | 1.32 % | 23.35 % | 1.33 % | 0.63 % | 0.45 % | 0.53 % | 1.68 % | 1.72 % | 1.80 % |
| No of Share Holders | 30,679 | 33,527 | 43,552 | 64,168 | 79,895 | 86,404 | 90,090 | 91,452 | 84,269 | 89,692 | 86,249 | 79,878 | 68,283 | 58,108 | 51,852 | 48,572 | 49,293 | 50,015 | 47,846 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 13.26 | 8 | 8 | 8 | 8 | 4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.03 | 0.36 | 0.39 | 0.67 | 0.46 | 0.26 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 19 Feb 2021 |  Dividend | ₹ 8.00 /share | 17 Feb 2021 | 2,163.55 | 2,011.85 |
| 22 Feb 2022 | Dividend | ₹ 8.00 /share | 21 Feb 2022 | 2,459.95 | 1,976.10 |
| 23 Feb 2023 | Dividend | ₹ 8.00 /share | 23 Feb 2023 | 1,289.35 | 1,348.60 |
| 17 Nov 2023 | Dividend | ₹ 4.00 /share | 17 Nov 2023 | 1,472.25 | 1,606.85 |
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 2,098.30 | 2,091.55 |
| 08 Nov 2024 |  Quarterly Result Announcement | NA | 08 Nov 2024 | 2,119.10 | 2,112.60 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,708.90 | 1,757.75 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 1,694.80 | 1,712.30 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 2,019.00 | 2,055.70 |
| 13 Aug 2025 | Annual General Meeting | NA | 13 Aug 2025 | 1,938.80 | 2,092.90 |
| 04 Nov 2025 | Quarterly Result Announcement | NA | 04 Nov 2025 | 1,953.20 | 2,004.45 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1 day ago
1 day agoUpdate On Schedule Of Earnings Conference Call For The Quarter And Half Year Ended September 30 20252 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
3 days agoCorporate Action-Board approves Dividend3 days ago
3 days agoUnaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 20253 days ago
3 days agoBoard Meeting Outcome for For The Meeting Held Today (November 04 2025)3 days ago
3 days agoGrant Of Stock Benefits3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoBoard Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025 And Declaration Of Interim Dividend If Any For The Financial Year 2025-2610 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 13, 2025
Oct 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Business Update For Q2FY26Oct 06, 2025
Oct 06, 2025Closure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 16, 2025
Sep 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Update On Schedule Of Earnings Conference Call For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 07, 2025
Aug 07, 2025Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for The Meeting Held Today (August 07 2025)Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 01, 2025
Aug 01, 2025Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 23, 2025
Jul 23, 2025Letter To Shareholders Containing Weblink Of 25Th Annual General Meeting And Annual Report For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 22, 2025
Jul 22, 2025Notice Of 25Th Annual General Meeting For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 21, 2025
Jul 21, 2025Disclosure Under Regulation 30 Of Listing RegulationsJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 08, 2025
Jul 08, 2025Business Update For Q1FY26Jul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 04, 2025
Jul 04, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 02, 2025
Jul 02, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 18, 2025
Jun 18, 2025Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 18 2025Jun 18, 2025
Jun 18, 2025Mutual Fund Holdings
HDFC Focused Fund Direct-Growth 
Kotak Small Cap Fund Direct-Growth 
Nippon India Small Cap Fund Direct- Growth 
Franklin India Small Cap Fund Direct-Growth 
Canara Robeco Small Cap Fund Direct - Growth 
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth 
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
Tata Business Cycle Fund Direct - Growth 
UTI Dividend Yield Fund Direct-Growth 
Sundaram Services Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 45.98
ATR(14)
Less Volatile 56.88
STOCH(9,6)
Neutral 72.09
STOCH RSI(14)
Neutral 76.71
MACD(12,26)
Bullish 10.46
ADX(14)
Weak Trend 18.59
UO(9)
Bearish 50.43
ROC(12)
Uptrend And Accelerating 1.75
WillR(14)
Neutral -66.81
About Metropolis Healthcare
Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical laboratories, including a global reference laboratory in Mumbai, regional reference laboratories, satellite laboratories, and express laboratories. Metropolis provides services to both B2B and B2C markets, covering 197 cities in India and has operations in several African countries. The company offers approximately 3,487 clinical laboratory tests and 530 profiles, and has expanded its network through acquisitions and mergers. Metropolis is known for its quality diagnostics and has received awards for customer service and healthcare excellence.
Listing Date
15 Apr, 2019(6 Years,
-7 days)
Chairperson NameAmeera Sushil Shah
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
